How and when to use immunotherapy and related toxicities

Brief Synopsis:

The use of immunotherapy is an active therapeutic approach for a subgroup of patients with metastatic triple negative breast cancer (TNBC). Although some activity was observed even in previously pretreated patients, immunotherapy seems to be more effective in the first-line setting. During this educational talk we will discuss the role of immunotherapy in advanced TNBC, which the optimal platform to assess PDL1 status is, how to select which patients will benefit more and how to manage the most common immune-related toxicities.